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Background: Despite extensive research, there is no consensus how Personality Disorders (PD) and PD features
aﬀect outcome for Major Depressive Disorder (MDD). The present study evaluated the eﬀects of PD (features) on
treatment continuation and eﬀectiveness in Cognitive Therapy (CT) and Interpersonal Psychotherapy (IPT) for
MDD.
Methods: Depressed outpatients were randomized to CT (n=72) and IPT (n=74). Primary outcome was de-
pression severity measured repeatedly with the Beck Depression Inventory-II (BDI-II) at baseline, three months,
at the start of each therapy session, at post-treatment and monthly during ﬁve months follow-up.
Results: Comorbid PD and PD features did not aﬀect dropout. Multilevel and Cox regression models indicated no
negative eﬀect of PD on BDI-II change and remission rates during treatment and follow-up, irrespective of the
treatment received. For both therapies, higher dependent PD features predicted overall lower BDI-II scores
during treatment, however this eﬀect did not sustain through follow-up. Cluster A PD features moderated
treatment outcome during treatment and follow-up: individuals with high cluster A PD features had greater BDI-
II reductions over time in CT as compared to IPT.
Limitations: Not all therapists and participants were blind to the assessment of PD (features), and assessments
were performed by one rater. Further research must investigate the state and trait dependent changes of PD and
MDD over time.
Conclusions: We found no negative impact of PD on the eﬀectiveness and treatment retention of CT and IPT for
MDD during treatment and follow-up. If replicated, cluster A PD features can be used to optimize treatment
selection.
1. Introduction
Individuals with major depressive disorder (MDD) often meet cri-
teria for DSM deﬁned co-morbid personality disorders (PD), in parti-
cular PD's grouped in cluster C: obsessive compulsive PD, dependent PD
and avoidant PD (Friborg et al., 2014). Despite extensive research
spanning several decades, results from research into the impact of co-
morbid PD on the eﬀectiveness of acute phase treatment for MDD is
equivocal; results vary from a negative association between the pre-
sence of a co-morbid PD and clinical outcome (Hardy et al., 1995;
Newton-Howes et al., 2014; Reich and Vasile, 1993; Sato et al., 1994) to
the absence of any diﬀerence between outcome in individuals with and
without co-morbid PD (De Bolle et al., 2011; Kool et al., 2005;
Moradveisi et al., 2013; Mulder, 2002). These inconsistencies across
studies are probably best explained by methodological problems. Un-
controlled study designs are common, allowing selection bias based on
clinicians’ decision-making. Nevertheless, the studies that used a ran-
domized design also reported inconsistent ﬁndings varying from no
diﬀerences between individuals with and without a co-morbid PD
(Hirschfeld et al., 1998; Maddux et al., 2009) to a negative eﬀect of PD
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on MDD outcome (DeRubeis et al., 2014; Fournier et al., 2008). Another
concern is that only a few studies provide data on the relationship
between PD and dropout (Kool et al., 2005), which can lead to biased or
inaccurate conclusions. The few studies that reported drop-out rates
have mixed results: some showed no diﬀerence between individuals
with and without PD (Fournier et al., 2008; Kool et al., 2003; Sullivan
et al., 1994), while others reported higher drop-out rates for individuals
with PD (Moradveisi et al., 2013). In addition, despite substantial dif-
ferences (e.g. depression severity) between individuals with and
without PD, multivariable models controlling for signiﬁcant con-
founders are rarely used (Casey et al., 2004; Mulder, 2002). Finally,
inconsistent ﬁndings could also be explained by diﬀerent outcomes on
self-report versus clinician-rated measures of personality pathology and
depression outcome (Mulder, 2002; Stanley and Wilson, 2006; Unger
et al., 2013).
Concerning the various treatment options for MDD, researchers and
clinicians alike have come to realize that a ‘one size ﬁts all’ approach is
not very eﬀective. A major challenge in health care research today is to
select the best treatment option for a given individual, a concept re-
ferred to as personalized medicine (Simon and Perlis, 2010). Therefore, it
is highly relevant to examine whether depressed individuals with co-
morbid PD respond diﬀerentially to evidence-based psychotherapies for
MDD. At present, both Cognitive Therapy (CT) and Interpersonal Psy-
chotherapy (IPT) are recommended as ﬁrst choice evidence-based
psychotherapies for MDD (Cuijpers et al., 2014). A recent trial se-
quential analysis showed that both treatments do not diﬀer in eﬀec-
tiveness for MDD when a diﬀerence of 4 BDI-II points is taken as futile
(Lemmens et al., 2015).
Previous research comparing CT and IPT head-to-head suggests
speciﬁc PD features as potential treatment moderators. The National
Institute of Mental Health Treatment of Depression Collaborative
Program found that depressed individuals with obsessive-compulsive
PD features were more likely to respond to IPT, while depressed par-
ticipants with more avoidant PD features responded better to CT
(Barber and Muenz, 1996). These results were partially replicated by
the Christchurch Psychotherapy for Depression Study, where in-
dividuals with MDD and comorbid PD features responded less well to
IPT compared to CT (Carter et al., 2011) particularly in individuals with
avoidant PD features (Joyce et al., 2007). In another study, depressive
PD features predicted better outcome in CT compared to IPT, while
other PD features did not predict diﬀerential treatment outcome (Ryder
et al., 2010). These inconsistencies might be explained by the use of
diﬀerent PD assessments, which complicates comparison of these
ﬁndings. Moreover, most studies use simple linear regression models,
while multilevel modeling is rarely used. The latter can explore the
dynamic and individual course of depression more accurately (De Bolle
et al., 2011).
The overall aim of the current study was to determine whether the
presence of a DSM PD diagnosis, aﬀected depressive symptom change
and treatment retention in CT and IPT during treatment and follow-up.
In addition, the eﬀect of PD on remission rates was evaluated, since
achieving remission is an evident treatment goal in CT and IPT.
Potential diﬀerences in these eﬀects between CT and IPT were ex-
amined. To acquire a more detailed understanding about cluster C PD
features, dimensional scores of obsessive-compulsive, avoidant and
dependent PD features as deﬁned by the DSM were calculated, together
with cluster A and cluster B PD feature scores. With these scores, gen-
eral and diﬀerential eﬀects of speciﬁc PD features on depressive
symptom change, treatment retention and remission were examined in
CT and IPT. Based on previous studies, we were unsure how PD aﬀected
depression outcomes and dropout in CT and IPT during treatment and
follow-up. Based on the previous comparisons between CT and IPT we
expected cluster C features, in particular obsessive-compulsive and
avoidant PD features to moderate treatment outcomes.
2. Methods
2.1. Design and participants
Data were collected in the context of a large randomized clinical
trial. A detailed description about sample characteristics, study design,
interventions, and main treatment outcome ﬁndings is provided else-
where (Lemmens et al., 2011; Lemmens et al., 2015). The study was
conducted at the mood disorders unit of the Maastricht Community
Mental Health Centre (RIAGG Maastricht) and included 182 out-
patients, 18–65 years of age, with a primary diagnosis of MDD (as
conﬁrmed with the Structured Clinical Interview for DSM-IV Axis I
disorders (SCID-I; First et al., 1995)). Other inclusion criteria were:
internet access, an email address, and suﬃcient knowledge of the Dutch
language. Exclusion criteria were a bipolar or chronic (current episode
> 5 years) depression, high acute suicide risk, concomitant pharma-
cological or psychological treatment, drugs and alcohol abuse/depen-
dence, and mental retardation (IQ < 80).
Participants were randomly allocated to CT (n=76), IPT (n=75), or
a Waiting List Condition (WLC; n=31). For the current analyses, we
limited the sample to data of individuals randomized to CT and IPT
(n=151). This sample participated in a treatment phase (0–7 months)
and a subsequent trial follow-up phase (7–12 months). Five participants
(4 in the CT group and 1 in the IPT group) were excluded in the current
study, because PD assessments were incomplete or missing. All parti-
cipants provided written informed consent and the study was approved
by the Medical Ethics Committee of Maastricht University Medical
Center. The study is registered at The Netherlands Trial Register, part of
the Dutch Cochrane Centre (ISRCTN 67561918).
2.2. Measures
2.2.1. Primary outcome
Primary outcome, depressive symptom severity, was assessed with
the Beck Depression Inventory, second edition (BDI-II; Beck et al.,
1996). BDI-II measurements included in this study were collected at
baseline, at the start of each therapy session and at 3, 7, 8, 9, 10, 11,
and 12 months.
2.2.2. Personality measures
PD diagnoses were administered prior to treatment using the
Structured Clinical Interview for DSM-IV Axis II (SCID-II; First et al.,
1997) by well-trained therapists that were participating in the study. In
addition, the results of the SCID-II assessment were available in the
patient record during treatment. Therefore, therapists and participants
were not blind to the results of the SCID-II assessment. Passive-Ag-
gressive PD and Depressive PD were excluded from the analyses, given
their position in the section of criteria sets for further study (American
Psychiatric Association, 2000). Dimensional PD scores were calculated
by summing up the items answered with ‘present’ for each PD criterion,
dismissing items that were scored ‘uncertain’ or ‘absent’. For the cluster
C PD features, we calculated individual avoidant PD features scores
(range 0–7), dependent PD features scores (range 0–8), and obsessive-
compulsive PD features scores (range 0–8). We calculated individual
cluster A PD features (range 0–23) and cluster B PD features (range
0–41) total scores providing two reference groups of other, non-Cluster
C, PD features.
2.3. Treatments and therapists
Both interventions consisted of 16–20 sessions of 45 min, depending
on the participants’ improvement, with an average of 17 sessions per
person (SD=2.9; Lemmens et al., 2015). Sessions were planned weekly
and allowed to be less frequently scheduled towards the end of therapy.
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Interventions were described in CT and IPT protocols following
guidelines by Beck et al. (1979) for CT, and guidelines by Klerman et al.
(1984) for IPT. Treatments were performed by ten licensed psycholo-
gist, psychotherapists, and psychiatrists (ﬁve in each condition) with on
average 9.1 years (SD=5.4) of clinical experience (range 4–21 years).
To avoid treatment contamination, therapist delivered exclusively CT
or IPT. All sessions were videotaped. The quality of treatment was rated
as good to excellent by independent assessors using the Cognitive
Therapy Scale for CT (mean=3.31, SD=0.93; Dobson et al. 1985) and
the short version of the IPT Adherence and Quality Scale for IPT
(mean=3.50, SD=0.70; Stuart, 2011). There were signiﬁcant diﬀer-
ences in therapy-speciﬁc behavior between conditions as indicated by
the Collaborative Study Psychotherapy Rating Scale (Hollon et al.,
1984, 1988) with higher CT-speciﬁc behavior in CT as compared to IPT
(mean score of 80.80 v. 52.42, t79.21=7.23, p < 0.001), and higher IPT-
speciﬁc behavior in IPT as compared to CT (85.75 v. 44.57,
t86.96=10.79, p < 0.001; Lemmens et al., 2015). The presence or ab-
sence of a comorbid PD diagnosis did not change therapy-speciﬁc be-
havior of the therapists; adherence remained equally well (results not
shown, all p-values > 0.3).
2.4. Statistical analysis
A detailed description of statistical analyses is presented in online
Data Supplement I. Diﬀerences in pretreatment (clinical) characteristics
and observed mean depression outcomes were examined for individuals
with and without PD using descriptive statistics. Study dropout (loss to
follow-up) and treatment dropout (discontinuation of the treatment
intervention) were compared between individuals with and without PD
(χ2) and treatment dropout was further investigated with a Cox re-
gression analysis.
Linear (2-level) mixed-eﬀects models were used to examine the ef-
fects of PD and PD features on BDI-II change for the treatment phase
(BDI-II scores measured at the start of each therapy session) and the
follow-up phase models (BDI-II scores at 7, 8, 9, 10, 11 and 12 months)
separately. All linear mixed-eﬀects models included the following ﬁxed
eﬀects: BDI-II baseline score (mean centered), a BDI-II baseline score ×
time interaction, time, treatment (centered at −0.5 for CT, +0.5 for
IPT) and a “time × treatment” interaction. For the time variable, the
endpoint was coded as zero (treatment phase model: session 20; trial
follow-up phase model: month 12). The eﬀect of PD was analyzed, by
adding a predictor of PD (centered at −0.5=no PD, +0.5=one or
more PD's) to the treatment and trial follow-up phase models, with “PD
× time”, “PD × condition” and “PD × time × condition” interactions.
To analyze the eﬀect of PD features, mean centered scores of avoidant
PD features, dependent PD features, obsessive-compulsive PD features,
cluster A and cluster B PD features were added simultaneously as
continuous predictors to the treatment and trial follow-up phase models
with “× time”, “× condition” and “time × condition” interactions. To
determine the pretreatment associations between PD features and BDI-
II baseline scores, Pearson correlation coeﬃcients were computed.
To examine eﬀects of PD and PD features on remission, we applied
two Cox regression models, with for each a diﬀerent deﬁnition of re-
mission based on the frequency of the BDI-II measurements. For the ﬁrst
model, referred to as the treatment phase Cox regression model, BDI-II
scores at the start of each weekly therapy session were used and re-
mission was deﬁned as a BDI-II score of < 10 for three consecutive
weeks. For the second model, referred to as the combined Cox regres-
sion model, BDI-II measures at 3, 7, 8, 9, 10, 11 and 12 months across
the treatment and trial follow-up phase were used and remission was
deﬁned as a BDI-II score < 10 at one of the assessment points. Dropouts
were censored after the last available observation. All models included
“condition” as a predictor. The eﬀect of PD was examined by adding PD
as a dichotomous predictor (yes/no) to the models, along with a “PD ×
condition” interaction. The eﬀect of PD features was examined by
adding avoidant PD features, dependent PD features, obsessive-
Table 1
Sample description: demographics, clinical characteristics, quality of life, treatment compliance and depression outcome at 7 and 12 months.
Cognitive Therapy (n=72) Interpersonal Psychotherapy (n=74)
Participants without PD Participants with PD Participants without PD Participants with PD
(n=43) (n=29) (n=54) (n=20)
Demographics
- Age, years: mean (SD) 41.7 (12.9) 41.2 (12.1) 41.5 (12.2) 41.0 (11.2)
- Female, n (%) 32 (74.4) 20 (69.0) 35 (64.8) 11 (55.0)
- Partner, n (%) 23 (53.5) 17 (58.6) 34 (63.0) 16 (80.0)
- Employed, n (%) 27 (62.8) 16 (55.2) 31 (57.4) 16 (80.0)
- Education, n (%)
Low, n (%) 8 (18.2) 7 (25.0) 7 (13.0) 6 (30.0)
Medium, n (%) 29 (67.4) 16 (55.2) 30 (55.6) 10 (50.0)
High, n (%) 6 (13.6) 6 (21.4) 17 (31.5) 4 (20.0)
Clinical characteristics
- BDI-II baseline score, mean (SD)* 25.9 (8.0)** 32.0 (8.7)** 30.9 (9.3) 32.4 (7.7)
- Recurrent depression, n (%) 18 (41.9) 16 (55.2) 24 (44.4) 11 (55.0)
- Axis I comorbidity, n (%) 15 (34.9) 17 (58.6) 26 (48.2) 12 (60.0)
- BSI, mean (SD)* 56.3 (24.8)** 78.6 (30.6)** 70.3 (27.5) 75.2 (32.6)
Functionality
- WSAS, mean (SD) 22.1 (8.1) 24.4 (7.0) 23.1 (7.0) 20.8 (7.7)
- EQ-5D, mean (SD) 0.6 (0.2) 0.6 (0.2) 0.6 (0.3) 0.6 (0.3)
- RAND-36, mean (SD) 46.7 (18.2) 46.8 (13.6) 44.3 (14.7) 43.8 (11.7)
Treatment retention
- Dropouts, n (%) 12 (27.9) 5 (17.2) 13 (24.1) 2 (10.0)
Depression outcome: at 7 months
- BDI-II, mean (SD) 13.6 (9.4) 13.3 (11.3) 17.1 (14.1) 14.3 (11.7)
Depression outcome: at 12 months
- BDI-II, mean (SD) 13.1 (11.3) 11.2 (11.0) 17.9 (16.1) 16.3 (12.4)
Note: PD=Personality Disorder; BDI-II=Beck Depression Inventory, second edition; BSI=Brief Symptom Inventory; WSAS=Work and Social Adjustment Scale; EQ-5D=EuroQol-5D;
SD=Standard Deviation.
* P < 0.05 diﬀerences between participants with PD and participants without PD.
** P < 0.01 diﬀerences between participants with PD and participants without PD within treatment group.
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compulsive PD features, cluster A PD features, cluster B PD features and
their interactions with condition simultaneously to the models.
All outcomes were tested at α=0.05 (two-tailed). For all models, we
conducted a sensitivity analyses by consecutively adding the following
baseline measures to the models: therapist, demographics (age, gender,
employment, level of education), clinical features (ﬁrst or recurrent
depression, general psychological distress (BSI; Derogatis and
Melisaratos, 1983), axis I comorbidity (SCID-I; First et al., 1995)) and
functionality (Work and Social Adjustment Scale (W& SAS; Mundt
et al., 2002), the RAND-36 (van der Zee and Sanderman, 1993) and the
EuroQol-6D (EQ-6D; EuroQol, 1990) for the EQ-5D).
3. Results
3.1. Descriptive statistics
In our sample of 146 participants, 49 individuals were diagnosed
with one (n=37; CT=19, IPT=18) or multiple PDs (n=12; CT=10,
IPT=2). The number of individuals with a PD diagnosis did not sig-
niﬁcantly diﬀer between the two treatment groups (CT=29, IPT=20,
χ2=2.87, p=0.09). The most prevalent PD in this sample was an
avoidant PD (46.0%), followed by obsessive-compulsive PD (31.7%),
paranoid PD (6.3%), borderline PD (6.3%), dependent PD (3.2%),
schizotypal PD (3.2%), schizoid Personality Disorder (1.6%), and PD
not otherwise speciﬁed (1.6%). Examining dimensional PD features,
participants had on average 1.8 avoidant PD features, 0.9 dependent PD
features, 1.5 obsessive-compulsive PD features, 1.3 cluster A PD fea-
tures and 1.3 cluster B PD features. These PD features did not appear to
signiﬁcantly diﬀer between the two treatments (all p's > 0.05).
Table 1 provides the diﬀerences in baseline demographics, clinical
characteristics, functionality measures, treatment compliance, and ob-
served mean treatment outcomes between participants with and
without PD in each treatment condition. Baseline BDI-II scores were
signiﬁcantly higher in participants with PD compared to participants
without PD (t (144)=2.28, p=0.02). In addition, higher levels of
general psychological distress (as measured with the BSI) and more axis
I comorbidity were found in participants with PD compared to parti-
cipants without PD (t (144)=2.61, p=0.01 and χ2 (1)=3.73,
p=0.053).
3.2. The eﬀect of Personality Disorder and PD features on study and
treatment dropout
Participants with and without PD did not diﬀer signiﬁcantly in
proportion of study and treatment dropouts (χ2 (1)=0.27, p=0.60 and
χ2 (1)=2.51, p=0.113). When further examining treatment dropout
with a Cox regression model, no signiﬁcant eﬀect of PD was found
(HR=0.59, p=0.33) and there was no signiﬁcant “PD x treatment in-
teraction” (HR=0.61, p=0.59). Obsessive-compulsive PD features,
dependent PD features, avoidant PD features, cluster A PD features and
cluster B PD features did not signiﬁcantly aﬀect treatment dropout, and
their interactions with treatment were not signiﬁcant (all p's > 0.3).
3.3. The eﬀect of Personality Disorder on BDI-II change and remission
Table 2 summarizes the results of the linear mixed-eﬀects models
estimating the eﬀects of PD, “PD × time”, “PD × condition”, and “PD
× time × condition” on BDI-II change in the treatment and trial follow-
up phase. There was no signiﬁcant eﬀect of PD on BDI-II change during
treatment and trial follow-up phase. Additionally, “PD × condition”
and “PD × time × condition” were not signiﬁcant, indicating no dif-
ferential eﬀect of PD on depressive symptom change between the two
interventions. During the treatment phase, 46 participants achieved
remission including 21 participants with PD (43.75% of all individuals
with PD) and 25 participants without PD (25.51% of all individuals
without PD). No signiﬁcant eﬀect of PD (HR=1.5; p=0.33) or the “PDTa
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× condition” interaction (HR=1.3; p=0.63) was found with the
treatment phase Cox regression model, indicating no (diﬀerential) ef-
fect of PD on time to remission. In the treatment and trial follow-up
phase combined, 74 participants achieved remission, 28 with PD
(57.1% of all individuals with PD) and 46 without PD (47.4% of all
individuals without PD). The combined Cox regression model did not
indicate a signiﬁcant eﬀect of PD on time to remission (HR=1.1;
p=0.69), and no signiﬁcant eﬀect of condition “PD × condition”
(HR=1.2, p=0.66) as well. Sensitivity analyses did not change these
results.
3.4. The eﬀect of Personality Disorder features on BDI-II change and
remission
Table 3 provides estimates of the eﬀects of avoidant PD features,
dependent PD features, obsessive-compulsive PD features, cluster A PD
features and cluster B PD features and their interactions with “× time”,
“× condition”, and “× time × condition” on BDI-II change during
treatment and follow-up phase. During the treatment phase a sig-
niﬁcant “dependent PD features × time” interaction was found, in-
dicating that higher dependent PD features predicted overall lower BDI-
II scores across the treatment phase. This eﬀect is illustrated in Fig. 1
with plots of the mean BDI-II scores for individuals with high and low
dependent features (groups created via a median split). The “dependent
Fig. 1. Mean Beck Depression Inventory-II (BDI-II) scores for individuals with low and
high dependent personality disorder features in the treatment phase. Note: PD:
Personality Disorder; Low and high dependent PD features: subgroups of individuals with
low and high dependent PD features were created via a medium split.
Fig. 2. Mean Beck Depression Inventory-II (BDI-II) scores for individuals with low and high cluster A personality disorder features for a) Cognitive Therapy and b) Interpersonal
Psychotherapy in the treatment phase. Note: PD: Personality Disorder; Low and high cluster A PD features: subgroups of individuals with low and high cluster A PD features were created
via a medium split.
Fig. 3. Mean Beck Depression Inventory-II (BDI-II) scores for individuals with low and high cluster A personality disorder features for a) Cognitive Therapy and b) Interpersonal
Psychotherapy in the trial follow-up phase. Note: PD: Personality Disorder; Low and high cluster A PD features: subgroups of individuals with low and high cluster A PD features were
created via a medium split.
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PD features × time” interaction was no longer signiﬁcant in the trail
follow-up phase. Signiﬁcant “cluster A PD features × time × condi-
tion” interactions were found in both the treatment and trial follow-up
phase. For IPT, individuals with high cluster A PD features had less BDI-
II decrease over time as compared to individuals with low cluster A PD
features, while cluster A PD features did not aﬀect BDI-II change in CT.
This moderating eﬀect is illustrated with plots of mean BDI-II scores for
participants with high and low cluster A PD features (groups created via
a medium split) in the treatment phase (Fig. 2) and trial follow-up
phase (Fig. 3). Obsessive-compulsive PD features, avoidant PD features
and cluster B PD features did not show signiﬁcant (interaction) eﬀects
in any of the models. Results were not aﬀected during sensitivity ana-
lyses.
The treatment phase Cox regression model indicated that obsessive-
compulsive PD features did signiﬁcantly aﬀect time to remission during
the treatment phase (HR=1.3; p=0.006) with more OCPD features
predicting faster remission for both treatments (no diﬀerential eﬀect).
However, this eﬀect was not signiﬁcant in the combined Cox regression
model covering both the treatment and trial follow-up phase. Avoidant,
dependent, cluster A and cluster B PD features did not aﬀect time to
remission in both the treatment phase and the combined Cox regression
models and no signiﬁcant “× condition” interactions with these feature
scores were found. Sensitivity analyses did not change these results.
Pearson correlation coeﬃcients between BDI-II baseline scores and
PD features were as follows: avoidant PD features (r=0.26), dependent
PD features (r=0.14), obsessive-compulsive PD features (r=0.10),
cluster A PD features (r=0.18) and cluster B PD features (r=0.08).
Given these weak correlations, it is unlikely that the described PD
features eﬀects on BDI-II change were due to pretreatment associations
between PD features and depression severity.
4. Discussion
The current study examined the impact of PD and PD features on
treatment dropout, depressive symptom change and remission in CT
and IPT during treatment and a ﬁve month follow-up phase. We found
that individuals with PD were more severely depressed prior to treat-
ment compared to individuals without PD. Despite these baseline dif-
ferences, PD (features) did not aﬀect dropout, remission rates and de-
pression severity change for CT and IPT. In addition, more subtle eﬀects
were found regarding speciﬁc PD features.
As often found in previous studies (Mulder, 2002), individuals with
a PD had a more complex clinical picture compared to individuals
without a PD prior to treatment, with higher depression severity, higher
general psychological distress and more axis I comorbidity. However,
PD did not negatively impacted depression severity change and re-
mission rates during treatment and follow-up. Moreover, the percen-
tage of individuals achieving remission was non-signiﬁcantly higher for
participants with PD, and individuals with and without PD had com-
parable mean post-treatment BDI-II scores, indicative of no adverse
eﬀect of PD.
Contrary to what is often assumed, no adverse eﬀects of PD (fea-
tures) on treatment retention in both CT and IPT were found. This is
consistent with most (Fournier et al., 2008; Kool et al., 2003; Sullivan
et al., 1994), but not all previous literature: one study reported that PD
was associated with higher dropout; however these ﬁndings may be
somewhat limited, since only a small proportion of the participants had
a PD (Moradveisi et al., 2013). Regarding MDD outcome, the current
study did not ﬁnd a (negative) impact of PD on depressive symptom
change and remission. With respect to previous head-to-head compar-
isons of CT and IPT, one study found similar results (Shea et al., 1990),
while another study reported an adverse eﬀect of PD on MDD outcome
in IPT as compared to CT (Joyce et al., 2007). However, comparing
these ﬁndings is diﬃcult since one study used another PD assessment
instrument and both studies compared pre- and posttreatment depres-
sion scores instead of our repeated measurements approach. Based on
our ﬁndings we suggest that CT and IPT can both attain clinical sig-
niﬁcant depressive change, irrespective of a more complex clinical
presentation at the start of treatment. With regard to the eﬀect of
speciﬁc PD features, our ﬁndings deviate from previous research. Our
ﬁnding that dependent PD features predicted a BDI-II decrease over
time across the treatment phase has not been reported previously. A
possible explanation could be that individuals with higher dependent
PD features respond initially better to contact with a therapist, but that
this eﬀect is lost towards treatment termination. The ﬁnding that par-
ticipants with high cluster A PD features fared better in CT compared to
IPT has been previously reported for schizoid symptoms (Joyce et al.,
2007). In addition, in a comparison of CT with pharmacotherapy and
behavioral therapy, cluster A PD features were associated with better
outcomes in CT for the long-term (Moradveisi et al., 2013). However,
these eﬀects were absent in the acute phase of MDD. Our ﬁndings might
be explained by the fact that individuals with higher cluster A PD
features respond better to a structured therapy in which the therapists
takes a more directive role. In addition, one could argue that focusing
on interpersonal problems is quite complex for individuals with cluster
A PD features. In previous research, avoidant PD features were found to
predict superior treatment outcome in CT compared to IPT (Barber and
Muenz, 1996; Joyce et al., 2007), a ﬁnding that was not replicated in
the current study. The absence of an eﬀect of cluster B PD features on
BDI-II change is in line with a study into MDD with comorbid border-
line PD of Bellino et al. (2007), although it should be noted that nu-
merous studies have reported otherwise (Agosti et al., 2009; Grilo et al.,
2005; Gunderson et al., 2011; Levenson et al., 2012; Skodol et al.,
2011). A possible explanation for our ﬁnding is that we included par-
ticipants who met criteria for a primary diagnosis of MDD with co-
morbid PD, and not participants with a primary PD diagnosis with
comorbid MDD.
The ﬁnding that comorbid PD did not aﬀect MDD outcome seems at
odds with a previous paper using a subset of the same data of this study.
This study reported that the presence of any PD predicted lower post-
treatment BDI-II scores (Huibers et al., 2015, 2016). These ﬁndings
derived from a linear regression model with 20 other variables, using a
completers sample (n=134), including diagnoses of Passive-Aggressive
and Depressive PD. We repeated our treatment phase analyses using the
same covariates, data subset and PD diagnoses to explain these con-
ﬂicting results, but our ﬁndings remained similar. However, after re-
moving the random slope (and the autoregressive structure for re-
siduals), a decreasing eﬀect of PD on BDI-II change became apparent
but was non-signiﬁcant (β=−1.97, p=0.11). This suggests that the
random eﬀects of the multilevel model are responsible for the diﬀer-
ences between the analyses, which is in line with our earlier statement
that multivariable linear regression approaches are not perfectly suited
to address the eﬀects of PD and PD features on treatment outcome re-
liably. The impact of adding a random slope to our model, underlines
the importance of modeling the erratic and individual symptom tra-
jectories of depression.
Contrary to previous ﬁndings (De Bolle et al., 2011), our sensitivity
analyses did not indicate an eﬀect of therapist diﬀerences on treatment
outcome. One of the possible reasons for the absence of a therapist
eﬀect, may be the (very) good to excellent quality of therapy, and the
absence of therapists diﬀerences in protocol adherence (Lemmens et al.,
2015).
4.1. Clinical implications
Translating our ﬁndings to clinical practice, a few recommendations
can be considered. Firstly, depressed individuals with or without co-
morbid cluster C PD beneﬁtted equally from both evidence-based psy-
chotherapies and higher premature treatment discontinuation in in-
dividuals with personality pathology was not observed. This is relevant
as co-morbid cluster C PD is highly prevalent in MDD (Friborg et al.,
2014) and research shows that depressed individuals with co-morbid
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PD are less likely to receive adequate MDD treatment (Black et al.,
1988; Charney et al., 1981; Lewis and Appleby, 1988). To avoid under-
treatment of MDD in individuals with a comorbid cluster C PD, ad-
herence to standard clinical treatment guidelines seems mandatory.
Second, based on these ﬁndings, depressed individuals with high cluster
A PD features could be advised to start with CT instead of IPT, although
replication of these results is needed.
4.2. Methodological considerations
The current study evaluated the impact of personality pathology on
MDD outcome in CT and IPT using state-of-the art multilevel modeling
with repeated measurement of depressive symptoms. These models
were corrected for baseline BDI-II diﬀerences to allow a fair comparison
between two initially diﬀerent participant groups. Other important
strengths of this study are the random allocation, the relative large
sample size, the low and reported dropout rates and an extensive in-
tegrity check (Lemmens et al., 2015) Since these data were collected in
an eﬀectiveness study (Lemmens et al., 2015), we can translate our
ﬁndings more directly to clinical practice, while beneﬁtting from the
controlled circumstances.
Our study has some limitations. First, MDD and PD diagnoses were
only assessed by one rater, so inter-rater reliability could not be tested.
Second, therapist and participants were not blind to the results of the
SCID-II assessment. This knowledge could have aﬀected therapeutic
strategies and the participant's motivation. Although our adherence
check showed no diﬀerence in therapy-speciﬁc behavior for individuals
with and without PD, therapeutic interventions could have been
adapted for individuals with PD (e.g. responsivity eﬀects, Stiles, 2009).
Third, dimensional scores of PD features were calculated by sum-
ming up the items answered with ‘present’ for each PD. It can be
doubted if every point of increase on these dimensional scales corre-
sponds to a comparable increase of PD severity. Fourth, we based our
primary outcome only on one self-report instrument and we did not
include a clinician-rated measure of depression severity change. The
magnitude of convergence between the two types of measurement is
uncertain given diﬀerent results in the literature (Cuijpers et al., 2010;
Vittengl et al., 2013). Fifth, since PD and PD features were only assessed
at baseline, we could not determine if these PD ﬁndings are state or trait
dependent. The PD assessment could be contaminated by the depressive
perspective (Fava et al., 2002; Joﬀe and Regan, 1988). To deal with
these complex concepts, a pragmatic approach is suggested: if measures
of PD (features) predict (diﬀerential) depression outcome when MDD is
diagnosed, then they are considered to be useful (Mulder, 2002). Sixth,
our primary outcome was the level of depressive symptomatology. It is
uncertain if diﬀerences in other life domains (e.g., quality of inter-
personal relations) would emerge between remitted individuals with
our without PD after successful treatment. Finally, since appointments
were allowed to be scheduled in a ﬂexible manner some participants
received one or two more therapy sessions during the trial follow-up
phase, but this is unlikely to impact our outcomes drastically.
4.3. Future directions
More research is needed to further explore our results. Since our
sample, in line with previous outpatient research (Friborg et al., 2014),
consisted predominantly of individuals with a cluster C diagnosis, our
considerations about cluster A and B PDs on MDD outcome in IPT and
CT should be interpreted with caution. Although our study demon-
strates promising results of cluster A PD features as potential treatment
moderators, further research is needed to replicate these ﬁndings. Since
cluster A PD features is a heterogeneous category, a more detailed
understanding about speciﬁc cluster A PD features is warranted. Ide-
ally, a ‘what ﬁts for whom’ algorithm, based on individual personality
features can be generated. While this study focused on the treatment
phase and a ﬁve-month trial follow-up phase, a number of studies
indicate an adverse eﬀect of PD on long-term MDD outcomes (Grilo
et al., 2010; Markowitz et al., 2007). Further research is needed to
examine the enduring eﬀects of PD and PD features on CT and IPT
outcomes over time. Preferably, when examining long-term outcome
eﬀects, PD and MDD should be simultaneously and frequently assessed
to determine state and trait dependent changes.
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